American and European Regulations

  • Giorgio Pajardi
  • C. Parolo
  • S. WillbrandEmail author
  • L. Hurst
  • L. B. Grablutz


In the last two decades, the topic on how to manage the access of new health technologies (including drugs, vaccines, medical devices, medical procedures, etc.) is on top of the agenda of the decision makers in health care in most of the developed countries.


  1. 1.
    All Wales Medicines Strategy Group. Final appraisal recommendation. Collagenase Clostridium histolyticum (Xiapex). Advice No. 1711. 2011.Google Scholar
  2. 2.
    Scottish Medicines Consortium. SMC advice. Collagenase clostridium histolyticum (Xiapex). 2011.Google Scholar
  3. 3.
    The British Society for Surgery of the Hand. BSSH evidence for surgical treatment (BEST). Dupuytren’s disease. 2008.Google Scholar
  4. 4.
    Gerber RA, Perry R, Thompson R, et al. Dupuytren’s contracture: a retrospective database analysis to assess clinical management and costs in England. BMC Musculoskelet Disord. 2011;12(1):73–83.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Starkweather KD, Lattuga S, Hurst LC, Badalamente MA, Guilak F, Sampson SP, Dowd A, Wisch D. Collagenase in the treatment of Dupuytren disease: an in vitro study. J Hand Surg. 1996;21A(3):490–5.CrossRefGoogle Scholar
  6. 6.
    Badalamente MA, Hurst LC. Enzyme injection as a nonoperative treatment for Dupuytren disease. Drug Deliv. 1996;3:35–40.CrossRefGoogle Scholar
  7. 7.
    Badalamente MA, Hurst LC. Enzyme injection as a nonsurgical treatment of Dupuytren’s disease. J Hand Surg. 2000;25A(4):629–36.CrossRefGoogle Scholar
  8. 8.
    Badalamente MA, Hurst LC, Hentz VR. Collagen as a clinical target: nonoperative treatment of Dupuytren disease. J Hand Surg. 2002;27A(5):788–98. This paper was selected for inclusion in the Yearbook of Orthopaedics, 2003.CrossRefGoogle Scholar
  9. 9.
    Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren contracture. J Hand Surg. 2007;32(A)(6):767–74.CrossRefGoogle Scholar
  10. 10.
    Pfizer. The hand report. A pan-European report on the impact of the hand condition, Dupuytren’s contracture. June 2011. Accessed 27 Mar 2012.Google Scholar
  11. 11.
    British Medical Association and Royal Pharmaceutical Company of Great Britain. British national formulary. BNF 63. London: BMJ Group and RPS Publishing; 2012.Google Scholar
  12. 12.
    Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan TD, Meals RA, Smith TN, Rodzvilla J. Injectable Collagenase Clostridium histolyticum for Dupuytren contracture. N Engl J Med. 2009;361:968–79.CrossRefPubMedGoogle Scholar
  13. 13.
    Gaston RG, Larsen SE, Pess GM, Coleman S, Dean B, Cohen BM, Kaufman GJ, Tursi JP, Hurst LC. The efficacy and safety of concurrent Collagenase Clostridium histolyticum injections for 2 Dupuytren contractures in the same hand: a prospective, multicenter study. J Hand Surg [Am]. 2015;40(10):1963–71.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Giorgio Pajardi
    • 1
  • C. Parolo
    • 2
  • S. Willbrand
    • 3
    Email author
  • L. Hurst
    • 4
  • L. B. Grablutz
    • 5
  1. 1.Department of Hand SurgeryS. Giuseppe MultiMedica Hospital, Università degli Studi MilanoMilanoItaly
  2. 2.Chirurgia plastica ricostruttiva ed estetica, Chirurgia della mano e Microchirurgia, UOC chirurgia della manoGruppo MultiMedica, Ospedale San GiuseppeMilanoItaly
  3. 3.Department of Hand SurgeryUppsala University HospitalUppsalaSweden
  4. 4.Department of OrthopaedicsStony Brook University Medical CenterStony BrookUSA
  5. 5.American Drugs Regulation ConsultantPhiladelphiaUSA

Personalised recommendations